The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
 
Guy Heinrich Maria Jerusalem
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichy Sankyo; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Novartis; Pfizer; Roche
Research Funding - Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; BMS; Lilly; Medimmune; Merck; Novartis; Pfizer; Roche
 
Yeon Hee Park
Honoraria - Merck; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Eisai; Pfizer; Roche
Research Funding - AstraZeneca; Merck; Novartis; Pfizer
Travel, Accommodations, Expenses - Merck; Novartis
 
Toshinari Yamashita
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Nihonkayaku (Inst); Taiho Pharmaceutical (Inst)
 
Sara A. Hurvitz
Stock and Other Ownership Interests - Ideal Implant (I); ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); sanofi (Inst); Seattle Genetics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Shanu Modi
Honoraria - Novartis
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Macrogenics
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Genentech; Seattle Genetics
Research Funding - Daiichi Sankyo; Novartis; Roche/Genentech; Seattle Genetics; Synta
Travel, Accommodations, Expenses - Daiichi Sankyo; Genentech
 
Fabrice Andre
Stock and Other Ownership Interests - Pegacsy
Research Funding - AstraZeneca (Inst); Daiichi (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I); Freeline Therapeutics (I)
Leadership - AMAG Pharmaceuticals (I); Freeline Therapeutics (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I); Freeline Therapeutics (I); vertex (I)
Honoraria - AstraZeneca; Celltrion; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Context Therapeutics; Daiichi Sankyo; Genentech/Roche; Ionis Pharmaceuticals; Macrogenics; Merck; Novartis; Seattle Genetics; Taiho Pharmaceutical
Research Funding - Genentech (Inst); Pfizer (Inst)
 
Xavier Gonzalez
Expert Testimony - Pierre Fabre
 
Peter S. Hall
Research Funding - AstraZeneca (Inst); Daiichi-Sanchyo (Inst); Eisai (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Benoit You
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clovis Oncology; Daiichi Sankyo Europe GmbH; ECS PROGASTRIN; GlaxoSmithKline; Immunomedics; LEK; Novartis; Roche/Genentech; TESARO
Research Funding - Clovis Oncology (Inst); Merck Serono (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS; MSD Oncology; Roche/Genentech
 
Cristina Saura
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Exeter Pharmaceuticals; MediTech; Merck Sharp & Dohme; Novartis; Pfizer; Pfizer; Philips; Philips; Pierre Fabre; Puma Biotechnology; Roche; Roche; Sanofi/Aventis; SeaGen; Zymeworks
Research Funding - AstraZeneca (Inst); Genentech (Inst); Macrogenics (Inst); Novartis (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Roche (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genomic Health; Novartis; Pfizer; Puma Biotechnology; Roche
 
Sung-Bae Kim
Honoraria - DAEHWA Pharmaceutical; ISU ABXIS
Consulting or Advisory Role - AstraZeneca; DAEHWA Pharmaceutical; ISU Abxis; Lilly (Inst)
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst)
 
Cynthia R. C. Osborne
Honoraria - Agendia; Breast Cancer Index; Guardant Health; Immunomedics; Seattle Genetics
Speakers' Bureau - Lilly; Novartis
Travel, Accommodations, Expenses - Lilly; Novartis
 
Yasuaki Sagara
Speakers' Bureau - AstraZeneca; Celltrion; Chugai Pharma; Eisai; Novartis; Taiho Pharmaceutical; Takeda
Research Funding - Gencurix (Inst)
 
Eriko Tokunaga
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly
 
Yali Liu
Employment - Bristol-Myers Squibb; Daiichi Sankyo
Stock and Other Ownership Interests - Bristol-Myers Squibb; Daiichi Sankyo
 
Jillian Cathcart
Employment - Daiichi Sankyo
 
Caleb C. Lee
Employment - Daiichi Sankyo, Inc.
 
Christophe Perrin
Honoraria - Daiichi Sankyo; Pfizer
Consulting or Advisory Role - Daiichi Sankyo; Pfizer
Travel, Accommodations, Expenses - Daiichi Sankyo; Pfizer